CC
STLN

Centiva Capital’s Starling Oncology STLN Stock Holding History

Centiva Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-224,245
Closed -$688K – 2211
2026
Q1 		$688K Buy
+224,245
New +$688K 0.01% 711
2021
Q2 		– Sell
-26,207
Closed -$261K – 1629
2021
Q1 		$261K Sell
26,207
-29,793
-53% -$317K 0.01% 859
2020
Q4 		$605K Buy
56,000
+6,000
+12% +$61.8K 0.02% 397
2020
Q3 		$518K Hold
50,000
– – 0.03% 327
2020
Q2 		$503K Buy
+50,000
New +$497K 0.03% 288

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Centiva Capital's STLN Position: Q2 2026 in Review

Centiva Capital sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 224,245 shares — an estimated $688K sold.

Centiva Capital first reported a position in STLN in Q2 2020 and held it in 5 quarters. The position peaked at $688K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Centiva Capital reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 224,245 Starling Oncology shares in Q2 2026, an estimated $688K.
  • Centiva Capital first reported a position in Starling Oncology in Q2 2020 and held it in 5 quarters.
  • Centiva Capital's Starling Oncology position peaked at $688K in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.